Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 1091

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 1091
---

basis of a single reportable segment due to the lack of discrete, precise financial information available to the chief operating decision
maker (“CODM”). The CODM is the Chief Executive Officer. The CODM does not review segment assets when assessing segment performance
and deciding how to allocate resources. During 2024, refinements were made to the financial reporting information and the Company began
reporting on two reportable segments which were generally determined based on the decision-making structure of the Company and the grouping
of similar products and services: Branded and ImprimisRx.

    ●
    The Branded segment includes activities of the Company’s
    FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of our branded products.

    ●
    The ImprimisRx segment represents activities in the Company’s
    ophthalmology-focused pharmaceutical compounding business.

    F-44

Segment contribution for the segments represents
net revenues less cost of sales, certain general and administrative expenses, selling and marketing expenses, and research and development
expenses. The Company does not evaluate the following items at the segment level:

    ●
    Selling, general and administrative expenses that result from shared
    infrastructure, including certain expenses associated with legal matters, public company costs (e.g. investor relations), Board of
    Directors and principal executive officers and other like shared expenses.

    ●
    Operating expenses within selling, general and administrative expenses
    that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition
    and other shared costs.

    ●
    Other select revenues and operating expenses including research and
    development expenses, amortization, and asset sales and impairments, net as not all such information has been accounted for at the
    segment level, or such information has not been used by all segments.

Segment net revenues, segment operating expenses
and segment contribution information consisted of the following:

SCHEDULE
OF SEGMENT NET REVENUES

    Branded  
    ImprimisRx  
    Consolidated 

    Year Ended December 31, 2024 

    Branded  
    ImprimisRx  
    Consolidated 
  
    Product sales, net 
    $115,120,000  
    $83,499,000  
    $198,619,000 
  
    Other revenues 
     995,000  
     -  
     995,000 
  
    Total revenues